JP Morgan Chase
OBIO icon

JP Morgan Chase’s Orchestra BioMed OBIO Stock Holding History

JP Morgan Chase’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$99.2K Buy
20,880
+16,622
+390% +$68K ﹤0.01% 6062
2026
Q1 		$17.3K Sell
4,258
-328
-7% -$1.4K ﹤0.01% 6597
2025
Q4 		$19K Buy
4,586
+4,116
+876% +$16.6K ﹤0.01% 6520
2025
Q3 		$1.17K Hold
470
– – ﹤0.01% 6973
2025
Q2 		$1.26K Sell
470
-11,482
-96% -$33.5K ﹤0.01% 6598
2025
Q1 		$51.2K Sell
11,952
-37,453
-76% -$186K ﹤0.01% 5872
2024
Q4 		$198K Buy
49,405
+38,535
+355% +$207K ﹤0.01% 5478
2024
Q3 		$55.9K Sell
10,870
-450
-4% -$2.94K ﹤0.01% 5954
2024
Q2 		$92.3K Buy
11,320
+5,124
+83% +$29.7K ﹤0.01% 5553
2024
Q1 		$32.7K Sell
6,196
-3,410
-35% -$23.1K ﹤0.01% 6088
2023
Q4 		$87.7K Hold
9,606
– – ﹤0.01% 5800
2023
Q3 		$83.8K Buy
9,606
+6,202
+182% +$41.7K ﹤0.01% 5590
2023
Q2 		$23.8K Buy
+3,404
New +$51.6K ﹤0.01% 5881

Other funds holding OBIO

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

JP Morgan Chase's OBIO Position: Q2 2026 in Review

JP Morgan Chase increased its Orchestra BioMed (OBIO) stake by 390% in Q2 2026, buying an estimated $68K and bringing the position to 20,880 shares worth $99.2K. The position accounts for ﹤0.01% of the portfolio, ranked #6062.

JP Morgan Chase first reported a position in OBIO in Q2 2023 and has held it in 13 quarters since. The position peaked at $198K in Q4 2024. 77 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

  • JP Morgan Chase held 20,880 shares of Orchestra BioMed worth $99.2K as of Q2 2026.
  • JP Morgan Chase bought 16,622 Orchestra BioMed shares in Q2 2026, an estimated $68K.
  • Orchestra BioMed made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #6062 holding.
  • JP Morgan Chase first reported a position in Orchestra BioMed in Q2 2023 and has held it in 13 quarters since.
  • JP Morgan Chase's Orchestra BioMed position peaked at $198K in Q4 2024.
  • 77 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.